^
    Back
    Association details:
    Biomarker:ENO1 deletion
    Cancer:Glioblastoma
    Drug Class:ENO1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Synthesis of phosphoramidate-based pro-drugs of the enzyme enolase for the treatment of ENO1-deleted glioblastoma

    Excerpt:
    While our first-generation prodrug inhibitor, POMHEX, demonstrated complete eradication of ENO1-deleted GBM in preclinical models...